Quantification of WT1 mRNA by competitive NASBA in AML patients

Kurume Medical Journal

Volumn 48, Issue 2, 2001, Pages 129-134

  Fukahori, Shigeki ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Competitive NASBA; Minimal residual disease; WT1 mRNA

Indexed keywords

DNA BINDING PROTEIN; MESSENGER RNA; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TRANSCRIPTION FACTOR; TUMOR PROTEIN; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; DNA-BINDING PROTEINS; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; WT1 PROTEINS;

EID: 0035223377     PISSN: 00235679     EISSN: None     Source Type: Journal    
DOI: 10.2739/kurumemedj.48.129     Document Type: Article

References (22)

1. Katherine MC, Tom G, Caryn YI, Alan JB, Jerry P et al. Isolation and characterization of a zic polypeptide gene at the human chromosome 11 Wills' tumor locus. Cell 1990; 60:509-520.
2. Manfred G, Annemarie P, Webster C, Rachael LN, Stuart H et al. Homozygous deletion in wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343:774-776.
3. Frank JR III. The WT1 wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993; 7:896-903.
4. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamaguti T et al. WT1 as a new prognostic factor and new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84:3071-3079.
5. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y et al. Long-term follow up of minimal residual disease in leukemia patients by monitoring WT1 (wilms tumor gene) expression levels. Blood 1996; 88:2267-2278.
6. Kobayashi M, Horie H, and Kawaguchi R. Quantitative analysis of WT1 mRNA using competitive NASBA and the clinical application. SRL HOUKAN 1999; 23:118-122. (in Japanese)
7. Compton J. Nucleic acid sequence-based amplification. Nature 1991; 350:91-92.
8. Faby E, Kwoh DY, and Gingeras TR. Self-sustained sequence replication (3sr): An isothermal transcription based amplification system alterative to PCR. PCR Methods Applications 1991; 1:25-33.
9. Daniela D, Vinceczo R, Giuseppe A, Silva De S, Alessandria S et al. Early detection of relapse by prospective reverse transcriptase polymerase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the gimemaaieop multicenter "aida" trial. Blood 1998; 92:784-789.
10. Tkachuk DC, Westbrook CA, Andreeff M, Donlon TA, Cleary ML et al. Detection of bcr-abl fusion in chronic myelogeneous leukemia. Science 1990; 50:559-562.
11. Kawasaki ES, Steven SC, Mazie YC, Stephen DS, Richard C et al. Diagnosis of chronic myeloid and acute lymphocytic leukemia by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acid Sci USA 1988; 85:5698-5702.
12. King-Underwood L, and Pritchard-Jones K. Wilms tumor (WT1) gene mutations occur mainly in acute leukemia and may confer drug resistance. Blood 1998; 91:2961-2968.
13. King-Underwood L, Renshaw J, and Pritchard-Jones K. Mutations in the wilms tumor gene WT1 in leukemias. Blood 1996; 87:2171-2179.
14. Hosoya N, Miyagawa K, Minami K, Yazuki Y, Hirai H et al. Mutation analysis of the WT1 gene in myelodys-plastic syndromes. Jpn J Cancer Res 1998; 89:821-824.
15. El-Rifai W, Tapani R, Kin V, Samia T, Sakari K et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia. British Journal of Haematology 1996; 92:365-369.
16. Giuseppina N, Richard AL, and Janet DR. Persistence of the 8; 21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82:712-715.
17. Khalid T, and John ALY. Monitoring of minimal residual disease by quantitative reverse transcription-polymerase chain reaction for AML 1-MTG8 transcripts in AML-M2 with t (8;21). Blood 1996; 88:3704-3709.
18. Downing JR, Head DR, Curcio-Brint AM, Hulshof MG, Motroni TA et al. An AML 1/ETO fusion transcript is consistently detected by RNA-based polymerase chain reaction in acute myelogenous leukemia containing the (8:21) (q22;q22) translocation. Blood 1993; 81:3704-3709.
19. James RCS, Subhash V, David MS, Pier-Paolo P, John MG et al. Quantification of PML-RARa transcripts in acute promyelocytic leukemia; explanation for the lack of RT-PCR for the detection of minimal residual disease and induction of the leukemia-specific mRNA by-alpha interferon. British Journal of Haematology 1996; 95:95-101.
20. Francesco LC, Diverio D, Pandolfi P, Biondi A, Rossi V et al. Molecular evaluation residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992; 340:1437-1438.
21. Jerald R, Gene G, Arthur L, Rachel A, Eileen B et al. Detection of bcr-abl transcripts in philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997; 89:2602-2609.
22. Tamaki H, Ogawa H, Ohyashiki K, Iwama H, Inoue K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13:393-399.